Key Takeaways Researchers at MUSC report that engineered mesenchymal stem cells reversed new-onset type 1 diabetes in mice, pointing to the disease’s immune response rather than just its symptoms. The cells were modified to overexpress a protein called alpha-1 antitrypsin, which calmed the autoimmune attack and protected insulin producing beta
Quick Summary Mesenchymal stem cell (MSC) therapy for IBD (Crohn’s disease and ulcerative colitis) reduces inflammation, supports repair of damaged intestinal tissue, and helps balance immune response. It is not a replacement for biologics or steroids but may work alongside them. Clinical trials show improved gut symptoms and mucosal healing
Quick Summary In 2026, stem cell therapy for diabetes shows measurable improvement in 60-80% of patients, including better blood sugar control, reduced insulin use, and improved insulin resistance. Type 2 diabetes patients often respond better than type 1. However, full remission remains uncommon, and results depend on disease duration, treatment
